In Friday’s Wall Street session, Aclaris Therapeutics Inc (NASDAQ:ACRS) shares traded at $1.26, unchanged from the previous session.
ACRS stock price is now -6.79% away from the 50-day moving average and -33.79% away from the 200-day moving average. The market capitalization of the company currently stands at $136.43M.
On December 23, 2024, H.C. Wainwright Upgraded its previous ‘Neutral’ rating to ‘Buy’ on the stock keeping its target price maintained at $20, while ‘Cantor Fitzgerald’ rates the stock as ‘Overweight’
In other news, Mehra Anand, Director bought 666,666 shares of the company’s stock on Nov 19 ’24. The stock was bought for $1,499,998 at an average price of $2.25. Upon completion of the transaction, the Director now directly owns 710,030 shares in the company, valued at $0.89 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 05 ’24, 10% Owner Leonard Braden Michael bought 206,025 shares of the business’s stock. A total of $256,357 was incurred on buying the stock at an average price of $1.24. This leaves the insider owning 14,250,000 shares of the company worth $17.95 million. A total of 14.78% of the company’s stock is owned by insiders.
During the past 12 months, Aclaris Therapeutics Inc has had a low of $0.95 and a high of $5.17. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 5.06, and a quick ratio of 5.06. The fifty day moving average price for ACRS is $1.3518 and a two-hundred day moving average price translates $1.9029 for the stock.
The latest earnings results from Aclaris Therapeutics Inc (NASDAQ: ACRS) was released for 2025-03-31. The net profit margin was -732.42% and return on equity was -91.03% for ACRS. The company reported revenue of $1.46 million for the quarter, compared to $2.4 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -39.32 percent.
